Background/Aims: Systemic corticosteroids are highly effective at inducing clinical remission in cases of acute exacerbation of Crohn’s disease (CD) and ulcerative colitis (UC); however, their use is limited by their frequent and sometimes severe side effects. Thus, a second generation of corticosteroids with less systemic effects has been developed. This review analyzed all of the studies on the new formulations of steroids with limited absorption (budesonide, budesonide MMX®, beclomethasone dipropionate and erythrocyte-mediated delivery of dexamethasone) in patients with CD and UC. Methods: All relevant articles published in English between September 1960 and April 2011 were reviewed. Results: Budesonide is superior to placebo, and as effective as systemic corticosteroids in inducing clinical remission in patients with ileo-colonic CD, but evidence of mucosal healing is limited. When administered as an MMX formula, budesonide can also effectively induce clinical remission in patients with UC, but budesonide alone is not effective in maintaining clinical remission in CD or UC. Beclomethasone dipropionate seems to be effective in patients with mild-to-moderate left-sided and extensive UC, while data on erythrocyte-mediated delivery of dexamethasone are encouraging but still limited. The safety profile for all these products is good but more studies are needed. Conclusion: Steroids remain the mainstay for the induction of clinical remission in cases of acute relapse of both CD and UC. Second-generation corticosteroids are an interesting alternative, with the advantage of high topical activity, less systemic toxicity and limited side effects.

Keywords:
Second-generation corticosteroids, Crohn’s disease, Ulcerative colitis
1.
Van Assche G, Dignass A, Panes J, et al: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4:7–27.
2.
Stange EF, Travis SP, Vermeire S, et al: European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008;2:1–23.
3.
Hayashi R, Wada H, Ito K, et al: Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500:51–62.
4.
Dignass A, Van Assche G, Lindsay JO, et al: The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62.
5.
Travis SP, Stange EF, Lemann M, et al: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008;2:24–62.
6.
Keenan GF: Management of complications of glucocorticoid therapy. Clin Chest Med 1997;18:507–520.
7.
Rutgeerts PJ: Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 2001;15:1515–1525.
8.
Lichtenstein GR, Feagan BG, Cohen RD, et al: Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–630.
9.
Summers RW, Switz DM, Sessions JT Jr, et al: National Cooperative Crohn’s Disease study: results of drug treatment. Gastroenterology 1979;77:847–869.
10.
Malchow H, Ewe K, Brandes JW, et al: European Cooperative Crohn’s Disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–266.
11.
Modigliani R, Mary JY, Simon JF, et al: Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811–818.
12.
Landi B, Anh TN, Cortot A, et al: Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647–1653.
13.
Ho GT, Chiam P, Drummond H, et al: The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319–330.
14.
Sparberg M, Kirsner JB: Long-term corticosteroid therapy for regional enteritis: an analysis of 58 courses in 54 patients. Am J Dig Dis 1966;11:865–880.
15.
Jones JH, Lennard-Jones JE: Corticosteroids and corticotrophin in the treatment of Crohn’s disease. Gut 1966;7:181–187.
16.
Lennard-Jones JE, Longmore AJ, Newell AC, et al: An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960;1:217–222.
17.
Truelove SC, Watkinson G, Draper G: Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962;2:1708–1711.
18.
Regueiro M, Loftus EV Jr, Steinhart AH, et al: Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006;12:979–994.
19.
Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067–1070.
20.
Ford AC, Bernstein CN, Khan KJ, et al: Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590–599; quiz 600.
21.
Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836–841.
22.
Tremaine WJ, Hanauer SB, Katz S, et al: Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748–1754.
23.
Bar-Meir S, Chowers Y, Lavy A, et al: Budesonide versus prednisone in the treatment of active Crohn’s disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115:835–840.
24.
Campieri M, Ferguson A, Doe W, et al: Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut 1997;41:209–214.
25.
Gross V, Andus T, Caesar I, et al: Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905–909.
26.
Rutgeerts P, Lofberg R, Malchow H, et al: A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–845.
27.
van Ierssel GJ, van der Sluys Veer A, Verspaget HW, et al: Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn’s disease. Immunopharmacology 1995;29:11–17.
28.
Escher JC: Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47–54.
29.
D’Haens G, Verstraete A, Cheyns K, et al: Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther 1998;12:419–424.
30.
Tursi A, Giorgetti GM, Brandimarte G, et al: Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006;12:I29–I32.
31.
Seow CH, Benchimol EI, Griffiths AM, et al: Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;3:CD000296.
32.
Benchimol EI, Seow CH, Otley AR, et al: Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009;1:CD002913.
33.
Lofberg R, Danielsson A, Suhr O, et al: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110:1713–1718.
34.
Ferguson A, Campieri M, Doe W, et al: Oral budesonide as maintenance therapy in Crohn’s disease – results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther 1998;12:175–183.
35.
Gross V, Andus T, Ecker KW, et al: Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. Budesonide Study Group. Gut 1998;42:493–496.
36.
Ewe K, Bottger T, Buhr HJ, et al: Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group. Eur J Gastroenterol Hepatol 1999;11:277–282.
37.
Hellers G, Cortot A, Jewell D, et al: Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. IOIBD Budesonide Study Group. Gastroenterology 1999;116:294–300.
38.
Cortot A, Colombel JF, Rutgeerts P, et al: Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut 2001;48:186–190.
39.
Hanauer S, Sandborn WJ, Persson A, et al: Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005;21:363–371.
40.
Schoon EJ, Bollani S, Mills PR, et al: Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005;3:113–121.
41.
Mantzaris GJ, Christidou A, Sfakianakis M, et al: Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis 2009;15:375–382.
42.
Sherlock ME, Seow CH, Steinhart AH, et al: Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;10:CD007698.
43.
Gross V, Bunganic I, Belousova EA, et al: 3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011;5:129–138.
44.
Hammond A, Andus T, Gierend M, et al: Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis. Hepatogastroenterology 2004;51:1345–1349.
45.
Fiorino G, Fries W, De La Rue SA, et al: New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010;17:1851–1857.
46.
Brunner M, Ziegler S, Di Stefano AF, et al: Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006;61:31–38.
47.
D’Haens GR, Kovacs A, Vergauwe P, et al: Clinical trial: preliminary efficacy and safety study of a new budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4:153–160.
48.
Foe K, Cutler DJ, Brown KF, et al: Metabolism kinetics of beclomethasone propionate esters in human lung homogenates. Pharm Res 2000;17:1007–1012.
49.
Kumana CR, Seaton T, Meghji M, et al: Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing’s syndrome or hypothalamic pituitary adrenal suppression. Lancet 1982;1:579–583.
50.
Bansky G, Buhler H, Stamm B, et al: Treatment of distal ulcerative colitis with beclomethasone enemas: high therapeutic efficacy without endocrine side effects. A prospective, randomized, double-blind trial. Dis Colon Rectum 1987;30:288–292.
51.
Mulder CJ, Endert E, van der Heide H, et al: Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. An adrenocortical approach. Neth J Med 1989;35:18–24.
52.
Halpern Z, Sold O, Baratz M, et al: A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991;13:38–41.
53.
van der Heide H, van den Brandt-Gradel V, Tytgat GN, et al: Comparison of beclomethasone dipropionate and prednisolone 21- phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988;10:169–172.
54.
Campieri M, Cottone M, Miglio F, et al: Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361–366.
55.
Gionchetti P, D’Arienzo A, Rizzello F, et al: Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol 2005;39:291–297.
56.
Biancone L, Gionchetti P, Blanco Gdel V, et al: Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007;39:329–337.
57.
Mulder CJ, Fockens P, Meijer JW, et al: Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549–553.
58.
Rizzello F, Gionchetti P, Galeazzi R, et al: Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001;18:261–271.
59.
Rizzello F, Gionchetti P, D’Arienzo A, et al: Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109–1116.
60.
Campieri M, Adamo S, Valpiani D, et al: Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17:1471–1480.
61.
Papi C, Aratari A, Moretti A, et al: Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2010;55:2002–2007.
62.
Nunes T, Barreiro-de Acosta M, Nos P, et al: Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU study. J Crohns Colitis 2010;4:629–636.
63.
Bossa F, Latiano A, Rossi L, et al: Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103:2509–2516.
64.
Annese V, Latiano A, Rossi L, et al: Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients – a pilot uncontrolled study. Am J Gastroenterol 2005;100:1370–1375.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.